Use these links to rapidly review the documentTABLE OF CONTENTS



UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549

---

FORM 10-Q

---

|(Mark One)                                                    |                                                                                         
|------------------------------------------------------------- | ----------------------------------------------------------------------------------------
|ý                                                             | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
|For the quarterly period ended March 31, 2005                
|OR                                                           
|o                                                             | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|For the transition period
from                             to

Commission File Number 0-28494

---

MILLENNIUM PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter)

|Delaware(State or other jurisdiction of incorporation or organization)                                  |  | 04-3177038(I.R.S. Employer Identification No.)
|------------------------------------------------------------------------------------------------------- |  | ----------------------------------------------
|40 Landsdowne Street, Cambridge, Massachusetts 02139(Address of principal executive offices) (zip code)
|(617) 679-7000(Registrant's telephone number, including area code)                                     

---

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ý    No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange
Act). Yes ý    No o

Number of shares of the registrant's Common Stock, $0.001 par value, outstanding on May 2, 2005: 307,601,526



---





MILLENNIUM PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE QUARTER ENDED MARCH 31, 2005

TABLE OF CONTENTS



|        |  |                                                                                                    |  | Page
|------- |  | -------------------------------------------------------------------------------------------------- |  | ----
|PART I  |  | FINANCIAL INFORMATION                                                                              |  |     
|Item 1. |  | Condensed Consolidated Financial Statements                                                        |  |     
|        |  | Condensed Consolidated Balance Sheets as of March 31, 2005 and December 31, 2004                   |  | 3   
|        |  | Condensed Consolidated Statements of Operations for the three months ended March 31, 2005 and 2004 |  | 4   
|        |  | Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2005 and 2004 |  | 5   
|        |  | Notes to Condensed Consolidated Financial Statements                                               |  | 6   
|Item 2. |  | Management's Discussion and Analysis of Financial Condition and Results of Operations              |  | 17  
|        |  | Risk Factors That May Affect Results                                                               |  | 30  
|Item 3. |  | Quantitative and Qualitative Disclosures about Market Risk                                         |  | 44  
|Item 4. |  | Controls and Procedures                                                                            |  | 45  
|PART II |  | OTHER INFORMATION                                                                                  |  |     
|Item 6. |  | Exhibits                                                                                           |  | 46  
|        |  | Signatures                                                                                         |  | 47  
|        |  | Exhibit Index                                                                                      |  | 48  

The following Millennium trademarks are used in this Quarterly Report on Form 10-Q:Millennium®, the Millennium "M"
logo and design (registered), Millennium Pharmaceuticals, VELCADE® (bortezomib) for Injection, and INTEGRILIN® (eptifibatide) Injection. All are covered by
registrations or pending applications for registration in the U.S. Patent and Trademark Office and many other countries. Campath® is a registered trademark of ILEX Pharmaceuticals, L.P.,
ReoPro® (abciximab) is a trademark of Eli Lilly & Company, Aggrastat® (tirofiban) is a trademark of Merck & Co., Inc., Thalomid® (thalidomide)
and Revlimid® are trademarks of Celgene Corporation and Angiomax® (bivalirudin) is a trademark of The Medicines Company.Other trademarks used in this
Quarterly Report on Form 10-Q are the property of their respective owners.

2

---





PART I    FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Millennium Pharmaceuticals, Inc.        Condensed Consolidated Balance Sheets

|                                                                                                                                                           |                                            | March 31, 2005 |            | December 31,
2004 |  
|---------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------ | -------------- | ---------- | ----------------- | -
|
|
|Assets                                                                                                                                                     |                                            |                |            |                   |  
|Current assets:                                                                                                                                            |                                            |                |            |                   |  
|Cash and cash equivalents                                                                                                                                  |                                            | $              | 13,869     |                   | $
|Marketable securities                                                                                                                                      |                                            |                | 562,152    |                   |  
|Accounts receivable, net of allowances                                                                                                                     |                                            |                | 128,816    |                   |  
|Inventory                                                                                                                                                  |                                            |                | 96,667     |                   |  
|Prepaid expenses and other current assets                                                                                                                  |                                            |                | 15,829     |                   |  
|                                                                                                                                                           |                                            |                |            |                   |  
|                                                                                                                                                           | Total current assets                       |                |            | 817,333           |  
|Property and equipment, net                                                                                                                                |                                            |                | 212,132    |                   |  
|Restricted cash                                                                                                                                            |                                            |                | 9,140      |                   |  
|Other assets                                                                                                                                               |                                            |                | 15,082     |                   |  
|Goodwill                                                                                                                                                   |                                            |                | 1,208,934  |                   |  
|Developed technology, net                                                                                                                                  |                                            |                | 330,433    |                   |  
|Intangible assets, net                                                                                                                                     |                                            |                | 62,403     |                   |  
|                                                                                                                                                           |                                            |                |            |                   |  
|                                                                                                                                                           | Total assets                               |                | $          | 2,655,457         |  
|                                                                                                                                                           |                                            |                |            |                   |  
|Liabilities and Stockholders' Equity                                                                                                                       |                                            |                |            |                   |  
|Current liabilities:                                                                                                                                       |                                            |                |            |                   |  
|Accounts payable                                                                                                                                           |                                            | $              | 24,637     |                   | $
|Accrued expenses                                                                                                                                           |                                            |                | 79,898     |                   |  
|Advance from Schering-Plough                                                                                                                               |                                            |                |           |                   |  
|Current portion of restructuring                                                                                                                           |                                            |                | 27,325     |                   |  
|Current portion of deferred revenue                                                                                                                        |                                            |                | 43,683     |                   |  
|Current portion of capital lease obligations                                                                                                               |                                            |                | 8,937      |                   |  
|                                                                                                                                                           |                                            |                |            |                   |  
|                                                                                                                                                           | Total current liabilities                  |                |            | 184,480           |  
|Other long term liabilities                                                                                                                                |                                            |                | 5,403      |                   |  
|Restructuring, net of current portion                                                                                                                      |                                            |                | 34,886     |                   |  
|Deferred revenue, net of current portion                                                                                                                   |                                            |                | 11,360     |                   |  
|Capital lease obligations, net of current portion                                                                                                          |                                            |                | 78,863     |                   |  
|Long term debt                                                                                                                                             |                                            |                | 105,461    |                   |  
|Commitments and contingencies                                                                                                                              |                                            |                |            |                   |  
|Stockholders' equity:                                                                                                                                      |                                            |                |            |                   |  
|Preferred Stock, $0.001 par value; 5,000 shares authorized, none issued                                                                                    |                                            |                |           |                   |  
|Common Stock, $0.001 par value; 500,000 shares authorized: 306,860 shares at March 31, 2005 and 306,399 shares at December 31, 2004 issued and outstanding |                                            |                | 307        |                   |  
|Additional paid-in capital                                                                                                                                 |                                            |                | 4,550,432  |                   |  
|Accumulated other comprehensive loss                                                                                                                       |                                            |                | (10,532    | )                 |  
|Accumulated deficit                                                                                                                                        |                                            |                | (2,305,203 | )                 |  
|                                                                                                                                                           |                                            |                |            |                   |  
|                                                                                                                                                           | Total stockholders' equity                 |                |            | 2,235,004         |  
|                                                                                                                                                           |                                            |                |            |                   |  
|                                                                                                                                                           | Total liabilities and stockholders' equity |                | $          | 2,655,457         |  
|                                                                                                                                                           |                                            |                |            |                   |  

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

---





Millennium Pharmaceuticals, Inc.        Condensed Consolidated Statements of Operations        (unaudited)

|                                           |                                                                     | Three Months Ended
March 31, |        
|------------------------------------------ | ------------------------------------------------------------------- | ---------------------------- | -------
|
|
|Revenues:                                  |                                                                     |                              |        
|                                           | Net product sales                                                   |                              | $      
|                                           | Co-promotion revenue                                                |                              |        
|                                           | Revenue under strategic alliances                                   |                              |        
|                                           |                                                                     |                              |        
|                                           |                                                                     | Total revenues               |        
|                                           |                                                                     |                              |        
|Costs and expenses:                        |                                                                     |                              |        
|                                           | Cost of sales (excludes amortization of acquired intangible assets) |                              |        
|                                           | Research and development                                            |                              |        
|                                           | Selling, general and administrative                                 |                              |        
|                                           | Restructuring                                                       |                              |        
|                                           | Amortization of intangibles                                         |                              |        
|                                           |                                                                     |                              |        
|                                           |                                                                     | Total costs and expenses     |        
|                                           |                                                                     |                              |        
|Loss from operations                       |                                                                     |                              | (38,268
|Other income (expense):                    |                                                                     |                              |        
|                                           | Investment income, net                                              |                              |        
|                                           | Interest expense                                                    |                              |        
|                                           | Gain on sale of equity interest in joint venture                    |                              |        
|                                           |                                                                     |                              |        
|Net loss                                   |                                                                     | $                            | (36,414
|                                           |                                                                     |                              |        
|Amounts per common share:                  |                                                                     |                              |        
|Net loss, basic and diluted                |                                                                     | $                            | (0.12  
|                                           |                                                                     |                              |        
|Weighted average shares, basic and diluted |                                                                     |                              | 306,590
|                                           |                                                                     |                              |        

The
accompanying notes are an integral part of these condensed consolidated financial statements.

4

---





Millennium Pharmaceuticals, Inc        Condensed Consolidated Statements of Cash Flows        (unaudited)

|                                                                       |                                                    | Three Months Ended
March 31, |         
|---------------------------------------------------------------------- | -------------------------------------------------- | ---------------------------- | --------
|
|
|Cash Flows from Operating Activities:                                  |                                                    |                              |         
|Net loss                                                               |                                                    | $                            | (36,414 
|Adjustments to reconcile net loss to cash used in operating activities |                                                    |                              |         
|                                                                       | Depreciation and amortization                      |                              |         
|                                                                       | Restructuring charges (reversals), net             |                              |         
|                                                                       | Amortization of deferred financing costs           |                              |         
|                                                                       | Realized (gain) loss on marketable securities, net |                              |         
|                                                                       | Stock compensation expense                         |                              |         
|Changes in operating assets and liabilities:                           |                                                    |                              |         
|                                                                       | Accounts receivable                                |                              |         
|                                                                       | Inventory                                          |                              |         
|                                                                       | Prepaid expenses and other current assets          |                              |         
|                                                                       | Restricted cash and other assets                   |                              |         
|                                                                       | Accounts payable and accrued expenses              |                              |         
|                                                                       | Advance from Schering-Plough                       |                              |         
|                                                                       | Deferred revenue                                   |                              |         
|                                                                       |                                                    |                              |         
|Net cash used in operating activities                                  |                                                    |                              | (110,207
|                                                                       |                                                    |                              |         
|Cash Flows from Investing Activities:                                  |                                                    |                              |         
|Investments in marketable securities                                   |                                                    |                              | (55,378 
|Proceeds from sales and maturities of marketable securities            |                                                    |                              | 175,015 
|Purchases of property and equipment                                    |                                                    |                              | (4,312  
|Other investing activities                                             |                                                    |                              | (3,995  
|                                                                       |                                                    |                              |         
|Net cash provided by investing activities                              |                                                    |                              | 111,330 
|                                                                       |                                                    |                              |         
|Cash Flows from Financing Activities:                                  |                                                    |                              |         
|Net proceeds from employee stock purchases                             |                                                    |                              | 1,363   
|Principal payments on capital leases                                   |                                                    |                              | (3,132  
|                                                                       |                                                    |                              |         
|Net cash (used in) provided by financing activities                    |                                                    |                              | (1,769  
|                                                                       |                                                    |                              |         
|Decrease in cash and cash equivalents                                  |                                                    |                              | (646    
|Equity adjustment from foreign currency translation                    |                                                    |                              | 79      
|Cash and cash equivalents, beginning of period                         |                                                    |                              | 14,436  
|                                                                       |                                                    |                              |         
|Cash and cash equivalents, end of period                               |                                                    | $                            | 13,869  
|                                                                       |                                                    |                              |         
|Supplemental Cash Flow Information:                                    |                                                    |                              |         
|Cash paid for interest                                                 |                                                    | $                            | 3,815   

The
accompanying notes are an integral part of these condensed consolidated financial statements.

5

---





Millennium Pharmaceuticals, Inc.        Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered
necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three months ended March 31, 2005 are not
necessarily indicative of the results that may be expected for the year ended December 31, 2005. For further information, refer to the financial statements and accompanying footnotes included
in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, which was filed with the Securities and Exchange Commission ("SEC") on March 8, 2005.

2. Summary of Significant Accounting Policies

Cash Equivalents, Marketable Securities and Other Investments

Cash equivalents consist principally of money market funds and corporate bonds with maturities of three months or less at the date of purchase. Marketable
securities consist primarily of investment-grade corporate bonds, asset-backed debt securities and U.S. government agency debt securities. Other
investments represent ownership in private companies in which the Company holds less than a 20 percent ownership position and does not otherwise exercise significant influence. The Company
carries such investments at the lower of cost or market unless significant influence can be exercised over the investee, in which case such securities are recorded using the equity method.

Management
determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. Marketable securities
at March 31, 2005 and December 31, 2004 are classified as "available-for-sale." Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in
a separate component of stockholders' equity. The cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and
accretion are included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities and other investments are included in
investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.

During
the three months ended March 31, 2005 and 2004, the Company recorded realized gains on marketable securities of $0.05 million and $0.7 million, respectively,
and realized losses on marketable securities of $0.7 million and $0.3 million, respectively.

Segment Information

Statement of Financial Accounting Standards ("SFAS") No. 131, "Disclosures about Segments of an Enterprise and Related Information" ("SFAS
No. 131"), establishes standards for the way that public business enterprises report information about operating segments in their financial statements. SFAS No. 131 also establishes
standards for related disclosures about products and services, geographic areas, and major customers.

6

---



The
Company operates in one business segment, which focuses on the research, development and commercialization of therapeutic products. All of the Company's product sales are currently
related to sales of VELCADE® (bortezomib) for Injection. All of the Company's co-promotion revenue is related to sales and development of INTEGRILIN® (eptifibatide) Injection.
The remainder of the Company's total revenue is related to its strategic alliances.

Strategic
alliance revenues from Ortho Biotech Products, L.P. ("Ortho Biotech"), including milestones, distribution fees on sales outside of the United States and reimbursement,
accounted for approximately
22 percent and 10 percent of consolidated revenues for the three months ended March 31, 2005 and 2004, respectively. There were no other significant customers under strategic
alliances in the three months ended March 31, 2005 and 2004, respectively.

Information Concerning Market and Source of Supply Concentration

INTEGRILIN® (eptifibatide) Injection has received regulatory approvals in the United States, the countries of the European Union and a number of other
countries for various indications. The Company and Schering-Plough Ltd. and Schering Corporation (collectively "SGP") co-promote INTEGRILIN in the United States and share any profits and
losses. In the European Union, GlaxoSmithKline plc ("GSK") exclusively markets INTEGRILIN. In addition, SGP sells INTEGRILIN in specified other areas outside of the United States and the European
Union and SGP pays the Company royalties based on these sales of INTEGRILIN.

The
Company relies on third-party contract manufacturers for the clinical and commercial production of INTEGRILIN. The Company has two manufacturers that provide eptifibatide, the active
pharmaceutical ingredient necessary to make INTEGRILIN for both clinical trials and commercial supply. Solvay, Societe Anonyme ("Solvay") one of the current manufacturers, owns the process technology
used by it and the other manufacturer for the production of the active pharmaceutical ingredient. The Company plans to submit its own alternative process technology for the production of eptifibatide
for approval in the United States, Europe and other countries, as required. The Company entered into an agreement with Solvay in January 2003 for an initial term of four years and one-year
renewal periods thereafter. The Company has one manufacturer that currently performs fill/finish services for INTEGRILIN. The Company is qualifying a second fill/finish supplier and has identified an
alternative packaging supplier to serve as future sources of supply for the United States. The FDA or other regulatory agencies must approve the processes or the facilities that may be used for the
manufacture of our marketed products. Some materials in process at these alternative suppliers are included in inventory.

VELCADE®
(bortezomib) for Injection has received approvals in the United States, the countries of the European Union and a number of other countries for the treatment of
certain multiple myeloma patients. The Company sells VELCADE in the United States through its oncology-specific sales force and Ortho Biotech and its affiliates sell VELCADE outside the United States
where approvals have been received.

The
Company also relies on third-party contract manufacturers for the manufacturing, fill/finish and packaging of VELCADE® (bortezomib) for Injection for both commercial
purposes and for ongoing clinical trials. The Company has established long-term supply relationships for the production of commercial supplies of VELCADE. The Company currently works with one
manufacturer to complete fill/finish for VELCADE and the Company is qualifying a second fill/finish supplier.

7

---



During
2004, the Company began distributing VELCADE in the United States through a sole-source distribution model where the Company sells directly to a third party which in turn
distributes to the wholesaler base. VELCADE inventory levels may fluctuate in the short-term as the Company's current wholesalers familiarize themselves with new distribution logistics.

Inventory

Inventory consists of currently marketed products and from time to time, product candidates awaiting regulatory approval which were capitalized based upon
management's judgment of probable near term commercialization. The Company assesses the probability of commercialization based upon several factors including estimated launch date, time to manufacture
and shelf life. At March 31, 2005 and December 31, 2004, inventory does not include amounts for products that have not been approved for sale.

Inventories
are stated at the lower of cost (first in, first out) or market. Inventories are reviewed periodically for slow-moving or obsolete status based on sales activity, both
projected and historical.

Inventory
consists of the following (in thousands):

March 31, 2005

December 31, 2004Raw materials

$
64,934

$
73,214Work in process


9,868


8,507Finished goods


21,865


15,553$
96,667

$
97,274


Goodwill and Intangible Assets

Intangible assets consist of specifically identified intangible assets. Goodwill is the excess of any purchase price over the estimated fair market value of net
tangible assets acquired not allocated to specific intangible assets.

Intangible
assets consist of the following (in thousands):

|                                 |                                     | March 31, 2005 |         | December 31, 2004 |  
|-------------------------------- | ----------------------------------- | -------------- | ------- | ----------------- | -
|
|Developed technology             |                                     | $              | 435,000 |                   | $
|                                 |                                     |                |         |                   |  
|Core technology                  |                                     | $              | 18,712  |                   | $
|Other                            |                                     |                | 20,060  |                   |  
|                                 |                                     |                |         |                   |  
|                                 | Total amortizable intangible assets |                |         | 38,772            |  
|Total indefinite-lived trademark |                                     |                | 59,000  |                   |  
|                                 |                                     |                |         |                   |  
|Total intangible assets          |                                     | $              | 97,772  |                   | $
|                                 |                                     |                |         |                   |  

On
February 12, 2002, the Company acquired COR Therapeutics, Inc. ("COR") for an aggregate purchase price of $1.8 billion. The transaction was recorded as a purchase
for accounting purposes and the Company's consolidated financial statements include COR's operating results from the date of the

8

---



acquisition.
The purchase price was allocated to the assets purchased and liabilities assumed based upon their respective fair values, with the excess of the purchase price over the estimated fair
market value of net tangible assets acquired allocated to in-process research and development, developed technology, trademark and goodwill.

During
the year ended December 31, 2002, the Company recorded a one-time charge of $242.0 million for acquired in-process research and development representing the
estimated fair value related to five incomplete projects that, at the time of the COR acquisition, had no alternative future use and for
which technological feasibility had not been established. The most significant purchased research and development project that was in-process at the date of the acquisition consisted of inhibitors of
specified growth factor receptors in the tyrosine kinase family. These inhibitors have the potential to reduce the narrowing of blood vessels. Cancers such as specified leukemias appear to harbor
activated forms of some of these receptors. This project represented 62 percent of the total in-process value and was in pre-clinical testing at the time of the acquisition. The Company has
advanced this project into phase I clinical testing. The Company discontinued the remaining four of the five in-process projects as part of its restructuring efforts.

COR's
developed technology consisted of an existing product, INTEGRILIN® (eptifibatide) Injection and related patents. This developed technology was determined to be
separable from goodwill and was valued at approximately $435.0 million. Because the INTEGRILIN name was well recognized in the marketplace and was considered to contribute to the product
revenue, the trademark was determined to be separable from goodwill. The INTEGRILIN trademark was valued at approximately $59.0 million and is considered to have an indefinite life.

The
excess of the purchase price over the fair value of the net tangible and identifiable intangible assets was recorded as goodwill. Intangible assets that were not specifically
identifiable, had indeterminate lives or were inherent in the continuing business and related to the Company as a whole were classified as goodwill. The significant factors contributing to the
existence of goodwill related to company management, a specialized cardiovascular sales force, market position and operating experience.

Amortization
of intangibles is computed using the straight-line method over the useful lives of the respective assets as follows:

Developed technology

13 yearsCore technology

4 yearsOther

2 to 7 years


Amortization
expense for the three months ended March 31, 2005 and 2004 was approximately $8.5 million and $8.4 million, respectively. In addition, in connection
with its restructuring initiative
discussed in Note 3, the Company recognized an impairment charge in the year ended December 31, 2003 of approximately $11.3 million for technology it no longer intended to pursue.

As
required by SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill and indefinite lived intangible assets are not amortized but are reviewed annually for impairment, or
more frequently if impairment indicators arise. Separable intangible assets that are not deemed to have an indefinite life are amortized over their useful lives and reviewed for impairment when events
or changes in circumstances suggest that the assets may not be recoverable. The Company tests for goodwill

9

---



impairment
annually, on October 1, and whenever events or changes in circumstances suggest that the carrying amount may not be recoverable.

On
October 1, 2004, the Company performed its annual goodwill impairment test and determined that no impairment existed on that date. The Company continually monitors business and
market conditions to assess whether an impairment indicator exists. If the Company were to determine that an impairment indicator exists, it would be required to perform an impairment test which might
result in a material impairment charge to the statement of operations.

Revenue Recognition

The Company recognizes revenue from the sale of its products, co-promotion collaboration and strategic alliances. The Company's revenue arrangements with multiple
elements are divided into separate units of accounting if specified criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and
reliable evidence of the fair value of the undelivered items. The consideration received is allocated among the separate units based on their respective fair values, and the applicable revenue
recognition criteria are applied to each of the separate units. Advance payments received in excess of amounts earned are classified as deferred revenue until earned.

Net product sales

The Company records product sales of VELCADE® (bortezomib) for Injection when delivery has occurred, title passes to the customer, collection is
reasonably assured and the Company has no further obligations. Allowances are recorded as a reduction to product sales for estimated returns and discounts at the time of sale. Costs incurred by the
Company for shipping and handling are recorded in cost of sales.

Co-promotion revenue

Co-promotion revenue includes the Company's share of profits from the sale of INTEGRILIN® (eptifibatide) Injection in co-promotion territories by SGP.
Also included in co-promotion revenue are reimbursements from SGP of the Company's manufacturing-related costs, development costs, advertising and promotional expenses associated with the sale of
INTEGRILIN within co-promotion territories and royalties from SGP on sales of INTEGRILIN outside of the co-promotion territory other than Europe. The Company recognizes revenue when SGP ships
INTEGRILIN to wholesalers and records it net of allowances, if any. The Company defers specified manufacturing-related expenses until the time SGP ships related product to its customers inside of co-
promotion territories. Advance from Schering-Plough on the balance sheet includes cash advances from SGP to the Company for the Company's prepayments to its manufacturers of INTEGRILIN and was paid to
SGP in the first quarter of 2005.

Revenue under strategic alliances

The Company recognizes revenue from nonrefundable license payments, milestone payments, royalties and reimbursement of research and development costs.
Nonrefundable upfront fees for which no further performance obligations exist are recognized as revenue on the earlier of when payments are received or collection is assured.

10

---



Nonrefundable
upfront licensing fees and guaranteed, time-based payments that require continuing involvement in the form of research and development, manufacturing or other
commercialization efforts by the Company are recognized as revenue:



Milestone
payments are recognized as revenue when the performance obligations, as defined in the contract, are achieved. Performance obligations typically consist of significant
milestones in the development life cycle of the related technology or product candidate, such as initiation of clinical trials, filing for approval with regulatory agencies and approvals by regulatory
agencies.

Royalties
are recognized as revenue when earned.

Reimbursements
of research and development costs are recognized as revenue as the related costs are incurred.

Advertising and Promotional Expenses

Advertising and promotional expenses are expensed as incurred. During the three months ended March 31, 2005 and 2004, advertising and promotional expenses
were $11.6 million and $8.5 million, respectively.

Net Loss Per Common Share

Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is
typically computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method. However, for all
periods presented, diluted net loss per share is the same as basic net loss per share as the inclusion of weighted-average shares of common stock issuable upon the exercise of stock options, warrants
and convertible debt would be antidilutive.

11

---





Comprehensive Loss

Comprehensive loss is composed of net loss, unrealized gains and losses on marketable securities and cumulative foreign currency translation adjustments. The
following table displays comprehensive loss (in thousands):

Three Months Ended
March 31,2005

2004Net loss

$
(36,414
)
$
(40,587
)Unrealized gain (loss) on marketable securities


(4,658
)

4,248Cumulative translation adjustments


79


(312
)Comprehensive loss

$
(40,993
)
$
(36,651
)


The
components of accumulated other comprehensive loss were as follows (in thousands):

March 31, 2005

December 31, 2004Unrealized loss on marketable securities

$
(10,031
)
$
(5,373
)Cumulative translation adjustments


(501
)

(580
)Accumulated other comprehensive loss

$
(10,532
)
$
(5,953
)


Stock-Based Compensation

The Company follows the intrinsic value method under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25") and
related interpretations, in accounting for its stock-based compensation plans, rather than the alternative fair value accounting method provided for under SFAS No. 123, "Accounting for
Stock-Based Compensation" ("SFAS No. 123"), as amended by SFAS No. 148, "Accounting for Stock-based CompensationTransition and Disclosure," ("SFAS No. 148"). Under
APB 25, when the exercise price of options granted equals the market price of the underlying stock on the date of grant, no compensation expense is recognized. In accordance with Emerging Issues Task
Force ("EITF") 96-18, the Company records compensation expense equal to the fair value of options granted to non-employees over the vesting period, which is generally the period of service.

The
following information regarding net loss and net loss per share has been determined as if the Company had accounted for its employee stock options and employee stock plan under the
fair value method prescribed by SFAS No. 123, as amended by SFAS No. 148. The resulting effect on net loss and net loss per share pursuant to SFAS No. 123 is not likely to be
representative of the effects in future periods, due to subsequent additional option grants and periods of vesting.

12

---



The
following table illustrates the effect on net loss and loss per share as if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based
employee compensation (in thousands, except per share amounts):

|                                                                                                                |  | Three Months Ended
March 31, |        
|--------------------------------------------------------------------------------------------------------------- |  | ---------------------------- | -------
|
|Net loss                                                                                                        |  | $                            | (36,414
|Add: Stock-based employee compensation as reported in the Statements of Operations                              |  |                              |       
|Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards |  |                              | (16,409
|                                                                                                                |  |                              |        
|Pro forma net loss                                                                                              |  | $                            | (52,823
|                                                                                                                |  |                              |        
|Amounts per common share:                                                                                       |  |                              |        
|Basic and dilutedas reported                                                                                   |  | $                            | (0.12  
|Basic and dilutedpro forma                                                                                     |  | $                            | (0.17  

The
weighted-average per share fair value of options granted during the three months ended March 31, 2005 and 2004 was $4.81 and $12.10, respectively.

The
fair value of stock options and common stock issued pursuant to the stock option and stock purchase plans at the date of grant were estimated using the Black-Scholes model with the
following weighted-average assumptions:

|                      |  | Stock Options
Three Months Ended March 31, |   | Stock Purchase Plan
Three Months Ended March 31 |  
|--------------------- |  | ------------------------------------------ | - | ----------------------------------------------- | -
|
|Expected life (years) |  | 5.3                                        |   | 5.5                                             |  
|Interest rate         |  | 4.11                                       | % | 2.62                                            | %
|Volatility            |  | .60                                        |   | .82                                             |  

The
Black-Scholes model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. Option valuation models
require the input of highly subjective assumptions including the expected stock price volatility. The Company's employee stock options have characteristics significantly different from those of traded
options and changes in the subjective inputs assumptions can materially affect the fair value estimate.

Through
the end of the second quarter of 2004, the fair value of stock options granted was determined utilizing a historical volatility rate. In the third quarter of 2004, the Company
reevaluated and subsequently changed its expected volatility assumption. The Company now uses the most recent three-year time period for purposes of calculating the expected volatility. Additionally,
the Company considered implied volatilities of currently traded options to provide an estimate based upon current trading activity. After considering other such factors as its stage of development,
the length of time the Company has been public and the impact of having two marketed products, the Company believes this volatility rate better reflects the expected volatility of its stock.

13

---



The
Company has never declared cash dividends on any of its capital stock and does not expect to do so in the foreseeable future.

Accounting Pronouncements

In December 2004, the FASB issued SFAS No. 123R (revised 2004), "Share-Based PaymentAn Amendment of FASB Statements No. 123 and
95" ("SFAS No. 123R"). SFAS No. 123R requires companies to calculate and record in the income statement the cost of equity instruments, such as stock options or restricted stock, awarded
to employees for services received. The cost of the equity instrument is to be measured based on the fair value of the instruments on the date they are granted and is required to be recognized over
the period during which the employees are required to provide services in exchange for the equity instruments. SFAS No. 123R is effective at the beginning of the first fiscal year beginning
after June 15, 2005, or January 1, 2006.

SFAS
No. 123R provides two alternatives for adoption:



The
Company plans to adopt SFAS No. 123R using the modified prospective method. As permitted by SFAS No. 123, the Company currently accounts for share-based payments to
employees using APB 25 intrinsic value method and, as such, generally recognizes no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123R's fair value method
will have a significant impact on the Company's result of operations, although it will have no impact on its overall financial position. The Company cannot accurately estimate at this time the impact
of adopting SFAS No. 123R as it will depend on market price, assumptions used and levels of share-based payments granted in future periods. However, had the Company adopted SFAS No. 123R
in a prior period, the impact would approximate the impact of SFAS No. 123 as described in the disclosure of pro forma net loss and loss per share in Note 2 above.

3. Restructuring

In December 2002 and June 2003, the Company took steps to realign its resources to become a commercially-focused biopharmaceutical company. The
Company discontinued specified discovery research efforts, reduced overall headcount, primarily in its discovery group and consolidated its research and development facilities. As of
December 1, 2002, the Company adopted SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" ("SFAS No. 146"). SFAS No. 146 requires that a
liability for a cost associated with an exit or disposal activity be recognized and measured initially at its fair value in the period in which the liability is incurred, except for one-time
termination benefits that meet specified requirements. These actions resulted in the recognition of restructuring charges in the fourth quarter of 2002 and the years ended 2003 and 2004. During 2005,
the Company may recognize additional restructuring charges for adjustments to the estimates of the remaining rental obligations, net of estimated sublease income, for facilities vacated.

14

---



The
Company anticipates additional restructuring charges during 2005 of between approximately $5.0 million and $20.0 million relating to potential adjustments to its
original estimates of the remaining rental obligations for facilities it vacated based upon its ability to secure subtenants in the time and manner included in its original estimates.

These
costs are included in restructuring in the statements of operations and other current and other long term liabilities on the balance sheet at March 31, 2005. The following
table displays the restructuring activity and liability balances (in thousands):

|                     |  | Balance at
December 31, 2004 |        | Charges |   | Payments |  | Other |         | Balance at
March 31, 2005
|-------------------- |  | ---------------------------- | ------ | ------- | - | -------- |  | ----- | ------- | -------------------------
|Termination benefits |  | $                            | 728    |         | $ |         |  | $     | (305    | )                        
|Facilities           |  |                              | 67,956 |         |   | 1,107    |  |       | (7,385  | )                        
|Contract termination |  |                              | 5,352  |         |   |         |  |       | (5,000  | )                        
|                     |  |                              |        |         |   |          |  |       |         |                          
|Total                |  | $                            | 74,036 |         | $ | 1,107    |  | $     | (12,690 | )                        
|                     |  |                              |        |         |   |          |  |       |         |                          

The
projected timing of payments of the remaining restructuring liabilities at March 31, 2005 is approximately $27.3 million due through March 31, 2006 and
$34.9 million thereafter through 2022.

Costs
of termination benefits relate to severance packages, out-placement services and career counseling for employees affected by the restructuring. Charges related to facilities
include estimated remaining rental obligations, net of estimated sublease income, for facilities that the Company no longer occupies. The Company's decisions to vacate specified facilities and abandon
the related leasehold improvements as well as terminate specified research programs were deemed to be impairment indicators under SFAS No. 144, "Accounting for the Impairment or Disposal of
Long-Lived Assets." As a result of performing the impairment evaluations, asset impairment charges were recorded to adjust the carrying value of the related long-lived assets to their net realizable
values. The fair values
of the assets were estimated based upon anticipated future cash flows, discounted at a rate commensurate with the risk involved.

4. Revenue and Strategic Alliances

The Company has entered into research, development, technology transfer and commercialization arrangements with major pharmaceutical and biotechnology companies
relating to a broad range of therapeutic products. These alliances provide the Company with the opportunity to receive various combinations of license fees, research funding, co-promotion revenue,
distribution fees and may provide additional payments contingent upon its achievement of research and regulatory milestones and royalties and/or profit shares if the Company's collaborations are
successful in developing and commercializing products.

Product Alliances

During the three months ended March 31, 2005, the Company recognized $20.0 million of milestone payments under its alliance with Ortho Biotech
relating to VELCADE® (bortezomib) for Injection and the achievement of agreed-upon sales levels of VELCADE.

15

---



In
January 2005, the transition of the INTEGRILIN® (eptifibatide) Injection marketing authorization for the European Union from SGP to GSK was completed and GSK began
selling INTEGRILIN in the countries of the European Union. During the three months ended March 31, 2005, the Company recognized approximately $2.5 million of strategic alliance revenue
related to the payment obligation of approximately $19.9 million from GSK. The remaining amount will be recognized ratably through December 2005.

During
September 2004, the Company initiated the process, contemplated by the original agreement with SGP, to transition U.S. distribution responsibilities for INTEGRILIN from SGP
to the Company. The Company expects this transition to take place during the fourth quarter of 2005, at the earliest.

SGP
continues to co-promote INTEGRILIN with the Company in the United States and sell the product in all other territories outside Europe, and continues to pay the Company royalties on
INTEGRILIN sales outside of the United States and Europe.

5. Convertible Debt

The Company had the following convertible notes outstanding at March 31, 2005:



Under
the terms of these notes, the Company is required to make semi-annual interest payments on the outstanding principal balance of the 5.0% notes on March 1 and
September 1 of each year, of the 4.5% notes on June 15 and December 15 of each year and of the 5.5% notes on January 15 and July 15 of each year. All required
interest payments to date have been made.

6. Subsequent Event

In April 2005, the Company recorded a realized gain of approximately $10.5 million from the sale of its cost method investment in TransForm
Pharmaceuticals, Inc. ("TransForm"). The Company expects to record an additional realized gain of approximately $2.8 million in the second half of 2006 upon the final settlement of the
escrowed portion of the sale proceeds. TransForm, a company specializing in the discovery of formulations and novel crystalline forms of drug molecules, was acquired by Johnson & Johnson in a
cash-for-stock transaction that closed in April 2005.

16

---





Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Our management's discussion and analysis of our financial condition and results of our operations include the identification of certain trends and other
statements that may predict or anticipate future business or financial results that are subject to important factors that could cause our actual results to differ materially from those indicated. See
"Risk Factors That May Affect Results."

Overview

We are a leading biopharmaceutical company focused on developing and commercializing breakthrough products in the areas of cancer, cardiovascular disease and
inflammatory disease. We currently market two leading products, one for cancer and one for cardiovascular disease. We also have other potential therapeutic products in various stages of clinical and
preclinical development in all three of our therapeutic areas of disease focus.

In
addition to our two marketed products, VELCADE and INTEGRILIN® (eptifibatide) Injection, we have eight drug candidates in development. Our business strategy is to develop
and commercialize important new medicines through clinical trials and regulatory approvals and to play a significant role in the marketing and sale of many of these products. We plan to develop and
commercialize many of our products on our own, but will also seek development and commercial collaborators on favorable terms or when we otherwise believe that doing so would be advantageous to us.

Our Products

VELCADE® (bortezomib) for Injection

VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved in the United States for
patients with multiple myeloma. We received accelerated approval from the Food and Drug Administration, or FDA, on May 13, 2003 to market VELCADE for the treatment of multiple myeloma patients
who have received at least two prior therapies and have demonstrated disease progression on their most recent therapy, commonly referred to as third line and beyond.

In
March 2005, we received approval from the FDA of our supplemental New Drug Application, or sNDA, for VELCADE for the treatment of patients with multiple myeloma who have
received at least one prior therapy, commonly referred to as second line, based on our completed phase III APEX clinical trial. This regulatory decision marks the full approval of the drug and
increases the approved market potential significantly.

The
European Commission granted Marketing Authorization for VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated
disease progression on their most recent therapy in Europe in April 2004. Under this Authorization, a single license was granted to Millennium for marketing VELCADE in the 15 member states of
the European Union, plus Norway and Iceland. VELCADE was also approved for marketing in the ten accession member countries when those countries officially joined the European Union on May 1,
2004. VELCADE has also been approved in a number of other countries, including Canada, Switzerland, Argentina, Israel, Bulgaria, Slovenia, South Korea and Mexico, bringing the total number of approved
countries to approximately 46.

In
April 2005, our collaborator, Ortho Biotech Products, L.P., or Ortho Biotech, received approval from the European Commission for VELCADE as a monotherapy for multiple myeloma
patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

17

---



The
FDA granted VELCADE fast track designation for relapsed and refractory mantle cell lymphoma, an aggressive form of non-Hodgkin's lymphoma, in November 2004. This designation
allows the FDA to accept on a rolling basis portions of a marketing application for review prior to the submission of a final document.

Ortho Biotech Collaboration

In June 2003, we entered into an agreement with Ortho Biotech to collaborate on the commercialization and continued clinical development of VELCADE. Under
the terms of the agreement, we retain all commercialization rights to VELCADE in the United States. Ortho Biotech and its affiliate, Janssen-Cilag, have agreed to commercialize VELCADE outside of the
United States and Janssen Pharmaceutical K.K. is responsible for Japan. We receive distribution fees from Ortho Biotech and its affiliates from sales of VELCADE® (bortezomib) for Injection
outside of the United States. We also retain an option to co-promote VELCADE with Ortho Biotech at a future date in specified European countries.

We
are engaged with Ortho Biotech in an extensive global program for further clinical development of VELCADE with the purpose of maximizing the commercial potential of VELCADE. This
program is investigating the potential of VELCADE to treat multiple forms of solid and hematological tumors, including continued clinical development of VELCADE for multiple myeloma. Ortho Biotech is
responsible for 40% of the joint development costs through 2005 and for 45% of those costs after 2005. In addition, we may receive payments from Ortho Biotech for achieving clinical development
milestones, regulatory milestones outside of the United States or agreed-upon sales levels of VELCADE.

INTEGRILIN® (eptifibatide) Injection

We co-promote INTEGRILIN in the United States in collaboration with Schering-Plough Corporation and Schering-Plough Ltd., together referred to as SGP, and
share profits and losses. GlaxoSmithKline plc, or GSK, markets INTEGRILIN in the European Union under a license from us. SGP markets INTEGRILIN in specified other areas outside of the United States
and the European Union.

SGP Collaboration

In April 1995, COR Therapeutics, Inc., or COR, entered into a collaboration agreement with SGP to jointly develop and commercialize INTEGRILIN on a
worldwide basis. We acquired COR in February 2002.

Under
our collaboration agreement with SGP, we generally share any profits or losses from the United States with SGP based on the amount of promotional efforts that each party
contributes. Since the United States launch of INTEGRILIN in June 1998, we have agreed to share promotional efforts in the United States equally with SGP, except for costs associated with
marketing programs specific to us. We
have granted SGP an exclusive license to market INTEGRILIN outside of the United States and the European Union, and SGP pays royalties to us based on sales outside of the United States and the
European Union.

During
September 2004, we initiated the process, contemplated by our original agreement with SGP, to transition United States distribution responsibilities for
INTEGRILIN® (eptifibatide) Injection from SGP to us. We expect this transition to take place during the fourth quarter of 2005, at the earliest. After the transition, we expect we will
continue to co-promote the product with SGP, but we will be responsible for distributing the product. As a result, we will recognize revenue for all sales of INTEGRILIN in the United States and pay
SGP co-promotion fees.

18

---



GSK License Agreement

In June 2004, we reacquired the rights to market INTEGRILIN in Europe from SGP and concurrently entered into a license agreement granting GSK exclusive
marketing rights to INTEGRILIN in Europe. In January 2005, the transition of the INTEGRILIN marketing authorizations for the European Union from SGP to GSK was completed, and GSK began selling
INTEGRILIN in the countries of the European Union. Subject to approval of the transfer from SGP to GSK of the relevant marketing authorizations, GSK will also market INTEGRILIN in other European
countries. Our commercialization alliance with GSK is designed to provide significant sales and marketing support from GSK to address market opportunities for INTEGRILIN in Europe. Under the terms of
the agreement, we are entitled to license fees and royalties from GSK on INTEGRILIN sales in Europe subject to the achievement of specified objectives.

Under
the license agreement with GSK, decisions regarding the ongoing marketing of INTEGRILIN are generally subject to the oversight of a joint steering committee with equal membership
from GSK and us. However, GSK has significant final decision-making authority with respect to European marketing issues. Our agreement with GSK continues until the later of December 31, 2014,
or as long as GSK continues to commercialize INTEGRILIN in any European country.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been
prepared in accordance with generally accepted accounting principles. The preparation of these financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the
reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, inventory, intangible assets
and goodwill. We base our estimates on historical experience and on various other factors that are believed to be appropriate under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While
our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included in our Form 10-K, filed with the SEC on
March 8, 2005, we believe the following accounting policies are most critical to aid in fully understanding and evaluating our reported financial results.

Revenue

We recognize revenue from the sale of our products, our co-promotion collaboration and strategic alliances. We divide our revenue arrangements with multiple
elements into separate units of accounting if specified criteria are met, including whether the delivered element has stand-alone value to the customer and whether there is objective and reliable
evidence of the fair value of the undelivered items. We allocate the consideration we receive among the separate units based on their respective fair values, and the applicable revenue recognition
criteria are applied to each of the separate units. We classify advance payments received in excess of amounts earned as deferred revenue until earned.

We
recognize revenue from the sales of VELCADE® (bortezomib) for Injection in the United States when delivery has occurred and title has transferred to the wholesalers. We
record allowances as a reduction to product sales for product returns and discounts at the time of sale. As VELCADE is a fairly new product, we estimate product returns based on an ongoing analysis of
industry trends for similar products and historical return patterns as they become available. VELCADE returns are

19

---



expected
to be generally low because the shelf life for the product is 18 months in the United States and we expect wholesalers not to significantly stock inventory due to the expensive nature
of the product. Additionally, we consider several factors in our estimation process including our internal sales forecasts, inventory levels as provided by wholesalers and third-party market research
data. During the fourth quarter of 2004, we began distributing VELCADE through a sole-source distribution model. As we continually monitor actual product returns and inventory levels in the domestic
distribution channel, we have and may, from time to time, take actions to reduce our product returns estimate. Doing so would result in increased product sales at the time the return estimate is
changed. If circumstances change or conditions become more competitive in the market for therapeutic products that address multiple myeloma, we may take actions to increase our product return
estimates. Doing so would result in an incremental reduction of product sales at the time the return estimate is changed. Accruals for rebates, chargebacks, and other discounts are immaterial as a
result of the recent introduction of VELCADE and the current lack of competitive product available.

We
recognize co-promotion revenue based on SGP's reported shipments of INTEGRILIN® (eptifibatide) Injection to wholesalers. Co-promotion revenue includes our share of the
profits from the sales of INTEGRILIN, reimbursements of our manufacturing-related costs, development costs, advertising and promotional expenses and royalties from SGP on sales of INTEGRILIN outside
of the co-promotion territory. We communicate with SGP to calculate our share of the profits from the sales of INTEGRILIN on a monthly basis. The calculation includes estimates of the amount of
advertising and promotional expenses and other costs incurred on a monthly basis. We also communicate with SGP to estimate royalties earned on sales outside of the co-promotion territory. Adjustments
to our estimates are based upon actual information that we receive subsequent to our reporting deadlines. Our estimates are adjusted on a monthly basis and historically have not been significant due
to periodic communication with SGP. Significant adjustments in future reporting periods could impact the timing and the amount of revenue to be recognized.

We
recognize nonrefundable upfront licensing fees and guaranteed, time-based payments that require continuing involvement in the form of research and development, manufacturing or other
commercialization efforts by us as strategic alliance revenue:



When
the period of deferral cannot be specifically identified from the contract, management estimates the period based upon other critical factors contained within the contract. We
continually review these estimates which could result in a change in the deferral period and might impact the timing and the amount of revenue recognized.

Milestone
payments are recognized as strategic alliance revenue when the performance obligations, as defined in the contract, are achieved. Performance obligations typically consist of
significant milestones in the development life cycle of the related technology, such as initiation of clinical trials, filing for approval with regulatory agencies and approvals by regulatory
agencies.

Royalties
are recognized as revenue when earned.

Reimbursements
of research and development costs are recognized as strategic alliance revenue as the related costs are incurred.

20

---



Inventory

Inventory consists of currently marketed products and from time to time product candidates awaiting regulatory approval which were capitalized based upon
management's judgment of probable near-term commercialization. We assess the probability of commercialization based upon several factors including estimated launch date, time to manufacture and shelf
life. At March 31, 2005 and December 31, 2004, inventory does not include amounts for products that have not been approved for sale. Inventories primarily represent raw materials used in
production, work in process and finished goods inventory on hand, valued at cost. Inventories are reviewed periodically for slow-moving or obsolete status based on sales activity, both projected and
historical. Our current sales projections provide for full utilization of the inventory balance. If product sales levels differ from projections or a launch of a new product is
delayed, inventory may not be fully utilized and could be subject to impairment, at which point we would record a reserve to adjust inventory to its net realizable value.

Intangible Assets

We have acquired significant intangible assets that we value and record. Those assets which do not yet have regulatory approval and for which there are no
alternative uses are expensed as acquired in-process research and development, and those that are specifically identified and have alternative future uses are capitalized. We use a discounted cash
flow model to value intangible assets at acquisition. The discounted cash flow model requires assumptions about the timing and amount of future cash inflows and outflows, risk, the cost of capital,
and terminal values. Each of these factors can significantly affect the value of the intangible asset. We engage independent valuation experts who review our critical assumptions for significant
acquisitions of intangibles. We review intangible assets for impairment on a periodic basis using an undiscounted net cash flows approach when impairment indicators arise. If the undiscounted cash
flows of an intangible asset are less than the carrying value of an intangible asset, the intangible asset is written down to the discounted cash flow value. Where cash flows cannot be identified for
an individual asset, the review is applied at the lowest group level for which cash flows are identifiable.

Goodwill

On October 1, 2004, we performed our annual goodwill impairment test and determined that no impairment existed on that date. However, since the date of
acquisition of COR, which generated a significant amount of goodwill, we have experienced a significant decline in market capitalization due to a decline in stock price. We continually monitor
business and market conditions to assess whether an impairment indicator exists. If we were to determine that an impairment indicator exists, we would be required to perform an impairment test which
could result in a material impairment charge to our statement of operations.

Accounting Pronouncements

In December 2004, the FASB issued SFAS No. 123R (revised 2004), "Share-Based PaymentAn Amendment of FASB Statements No. 123 and
95" ("SFAS No. 123R"). SFAS No. 123R requires companies to calculate and record in the income statement the cost of equity instruments, such as stock options or restricted stock, awarded
to employees for services received. The cost of the equity instrument is to be measured based on the fair value of the instruments on the date they are granted and is required to be recognized over
the period during which the employees are required to provide services in exchange for the equity instruments. SFAS No. 123R is effective at the beginning of the first fiscal year beginning
after June 15, 2005, or January 1, 2006.

21

---



SFAS
No. 123R provides two alternatives for adoption:



We
plan to adopt SFAS No. 123R using the modified prospective method. As permitted by SFAS No. 123, we currently account for share-based payments to employees using APB 25
intrinsic value method and, as such, generally recognize no compensation cost for employee stock options. Accordingly, the adoption of SFAS No. 123R's fair value method will have a significant
impact on our result of operations, although it will have no impact on our overall financial position. We cannot accurately estimate at this time the impact of adopting SFAS No. 123R as it will
depend on our market price, our assumptions used and levels of share-based payments granted in future periods. However, had we adopted SFAS No. 123R in a prior period, the impact would
approximate the impact of SFAS No. 123 as described in the disclosure of pro forma net loss and loss per share in Note 2 to our condensed consolidated financial statements.

22

---



Results of Operations

(dollars
in thousands)

|                        |                                                                     | Three Months Ended
March 31, |         |        |        
|----------------------- | ------------------------------------------------------------------- | ---------------------------- | ------- | ------ | -------
|
|
|Revenues:               |                                                                     |                              |         |        |        
|                        | Net product sales                                                   |                              | $       | 44,795 |        
|                        | Co-promotion revenue                                                |                              |         | 42,826 |        
|                        | Revenue under strategic alliances                                   |                              |         | 36,090 |        
|                        |                                                                     |                              |         |        |        
|                        |                                                                     | Total revenues               |         |        | 123,711
|                        |                                                                     |                              |         |        |        
|Costs and expenses:     |                                                                     |                              |         |        |        
|                        | Cost of sales (excludes amortization of acquired intangible assets) |                              |         | 14,581 |        
|                        | Research and development                                            |                              |         | 86,154 |        
|                        | Selling, general and administrative                                 |                              |         | 51,637 |        
|                        | Restructuring                                                       |                              |         | 1,107  |        
|                        | Amortization of intangibles                                         |                              |         | 8,500  |        
|                        |                                                                     |                              |         |        |        
|                        |                                                                     | Total costs and expenses     |         |        | 161,979
|                        |                                                                     |                              |         |        |        
|Loss from operations    |                                                                     |                              | (38,268 | )      |        
|Other income (expense): |                                                                     |                              |         |        |        
|                        | Investment income, net                                              |                              |         | 4,442  |        
|                        | Interest expense                                                    |                              |         | (2,588 | )      
|                        | Gain on sale of equity interest in joint venture                    |                              |         |       |        
|                        |                                                                     |                              |         |        |        
|Net loss                |                                                                     | $                            | (36,414 | )      | $      
|                        |                                                                     |                              |         |        |        

Revenues

Total revenues increased 34% to $123.7 million in the first quarter of 2005 from the same period in 2004. The increase is due primarily to the achievement
of milestones under our collaborations with Ortho Biotech, as well as increased net product sales of VELCADE® (bortezomib) for Injection.

In
May 2003 we received FDA approval to market VELCADE and began shipping to wholesalers. Net product sales of VELCADE increased 51% to $44.8 million in the first quarter
of 2005 from $29.6 million in the same period in 2004, primarily reflecting increased use of the product. Reserves for product returns, chargebacks and discounts represent approximately 5% to
6% of gross product sales in the first quarters of 2005 and 2004. Product sales from VELCADE® (bortezomib) for Injection represent approximately 36% of our first quarter of 2005 total
revenues and 32% of our total revenues in the same period in 2004.

Co-promotion
revenue decreased 10% to $42.8 million in the first quarter of 2005 from $47.8 million in the same period in 2004. This decrease is primarily due to lower net
reimbursement from SGP under our collaboration agreement, offset by increased product sales in the United States. U.S. product sales, as provided to us by SGP, were $71.4 million for the first
quarter of 2005, a 5% increase over sales in the same period of 2004. Co-promotion revenue represents approximately 35% of our first quarter of 2005 total revenues and 52% of our total revenues in the
same period in 2004.

Revenue
under strategic alliances increased to $36.1 million in the first quarter of 2005 from $15.1 million in the same period in 2004. The increase is primarily due to
the recognition of milestone

23

---



payments
of approximately $20.0 million in the first quarter of 2005 as a result of the achievement of specified sales levels of VELCADE outside of the United States and worldwide, as well as
revenue recognized as a result of the successful transfer of the central marketing authorization of INTEGRILIN® (eptifibatide) Injection in Europe and related activities to GSK.

We
expect revenue under strategic alliances to fluctuate depending on the level of revenues earned for ongoing development efforts, the level of milestones achieved and the number of
alliances we may enter into in the future with major pharmaceutical companies.

Cost of Sales

Cost of sales decreased 8% to $14.6 million in the first quarter of 2005 from $15.8 million in the same period in 2004. Cost of sales includes
manufacturing-related expenses associated with the sales of VELCADE and INTEGRILIN. The decrease was primarily driven by proportionately higher sales of VELCADE.

Research and Development

Research and development expenses decreased 11% to $86.2 million in the first quarter of 2005 from $96.3 million in the same period in 2004. This
decrease primarily reflects the successful completion of our phase III APEX trial for VELCADE, as well as our continued focus on resource management and allocation.

In
addition to our ongoing clinical trials of INTEGRILIN and VELCADE, we have eight drug candidates in late preclinical and clinical development. The following chart summarizes the
applicable disease indication and the clinical or preclinical trial status of these eight drug candidates.

24

---



|Product Description                                                                                     |  | Disease Indication                                                            |  | Current Trial Status                                                                                             
|------------------------------------------------------------------------------------------------------- |  | ----------------------------------------------------------------------------- |  | -----------------------------------------------------------------------------------------------------------------
|Cancer                                                                                                  |  |                                                                               |  |                                                                                                                  
|MLN2704 is a targeting monoclonal antibody vehicle conjugated to toxin DM1                              |  | Prostate cancer                                                               |  | phase I/phase II                                                                                                 
|MLN518 is a small molecule Receptor Tyrosine Kinase, or RTK, that inhibits the F1t-3 Kinase             |  | Acute myeloid leukemia                                                        |  | phase I/phase II                                                                                                 
|MLN8054 is a small molecule inhibitor of Aurora kinases                                                 |  | Solid tumor cancers                                                           |  | preclinical                                                                                                      
|Cardiovascular Diseases                                                                                 |  |                                                                               |  |                                                                                                                  
|MLN2222 is a recombinant protein that is designed to block complement at both the C3 and C5 convertases |  | Reperfusion injury in patients undergoing cardiac surgeries                   |  | phase I                                                                                                          
|Inflammatory Diseases                                                                                   |  |                                                                               |  |                                                                                                                  
|MLN1202 is a humanized monoclonal antibody directed against CCR2                                        |  | Rheumatoid arthritis
Multiple sclerosis
Secondary atherosclerosis
Scleroderma |  | phase II
preclinical with phase IIa planned
preclinical with phase IIa planned
preclinical with phase IIa planned
|MLN3897 is a small molecule CCR1 inhibitor                                                              |  | Chronic inflammatory diseases such as rheumatoid arthritis                    |  | phase I with phase IIa planned                                                                                   
|MLN02 is a humanized monoclonal antibody directed against the a4ß7 receptor                             |  | Crohn's disease
Ulcerative colitis                                            |  | preclinical with prior phase II data
preclinical with prior phase II data                                        
|MLN3701is a small molecule CCR1 inhibitor backup to MLN3897                                             |  | Chronic inflammatory diseases such as rheumatoid arthritis                    |  | preclinical                                                                                                      

Completion of clinical trials may take several years or more and the length of time can vary substantially according to the type, complexity,
novelty and intended use of a product candidate. The types of costs incurred during a clinical trial vary depending upon the type of product candidate and the nature of the study.

We
estimate that clinical trials in our areas of focus are typically completed over the following timelines:

|Clinical Phase |  | Objective                                                                                        |  | Estimated Completion Period
|-------------- |  | ------------------------------------------------------------------------------------------------ |  | ---------------------------
|Phase I        |  | Establish safety in humans, study how the drug works, metabolizes and interacts with other drugs |  | 1-2 years                  
|Phase II       |  | Evaluate efficacy, optimal dosages and expanded evidence of safety                               |  | 2-3 years                  
|Phase III      |  | Confirm efficacy and safety of the product                                                       |  | 2-3 years                  

Upon successful completion of phase III clinical trials of a product candidate, we intend to submit the results to the FDA to support regulatory
approval. However, we cannot be certain that any of our product candidates will prove to be safe or effective, will receive regulatory approvals, or will be successfully commercialized. Our clinical
trials might prove that our product candidates may not be effective in treating the disease or have undesirable or unintended side effects, toxicities or other characteristics that require us to cease
further development of the product candidate. The cost to take a product candidate through clinical trials is dependent upon, among other things, the disease

25

---



indications,
the timing, the size and dosing schedule of each clinical trial, the number of patients enrolled in each trial and the speed at which patients are enrolled and treated. We could incur
increased product development costs if we experience delays in clinical trial enrollment, delays in the evaluation of clinical trial results or delays in regulatory approvals.

Some
products that are likely to result from our research and development projects are based on new technologies and new therapeutic approaches that have not been extensively tested in
humans. The regulatory requirements governing these types of products may be more rigorous than for conventional products. As a result, it is difficult to estimate the nature and length of the efforts
to complete such products as we may experience a longer regulatory process in connection with any products that we develop based upon these new technologies or therapeutic approaches. In addition,
ultimate approval for commercial manufacturing and marketing of our products is dependent on the FDA or applicable approval body in the country for which approval is being sought, adding further
uncertainty to
estimated costs and completion dates. Significant delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our product candidates.

Due
to the variability in the length of time necessary to develop a product, the uncertainties related to the estimated cost of the projects and ultimate ability to obtain governmental
approval for commercialization, accurate and meaningful estimates of the ultimate cost to bring our product candidates to market are not available.

We
budget and monitor our research and development costs by type or category, rather than by project on a comprehensive or fully allocated basis. Significant categories of costs include
personnel, clinical, third party research and development services and laboratory supplies. In addition, a significant portion of our research and development expense is not tracked by project as it
benefits multiple projects or our technology platform. Consequently, fully loaded research and development cost summaries by project are not available.

Given
the uncertainties related to development, we are currently unable to reliably estimate when, if ever, our product candidates will generate revenue and cash flows. We do not expect
to receive net cash inflows from any of our major research and development projects until a product candidate becomes a profitable commercial product.

Selling, General and Administrative

Selling, general and administrative expenses increased 15% to $51.6 million in the first quarter of 2005 from $44.8 million in the same period in
2004. The increase is primarily from increased sales and marketing spend associated with the preparation for the launch of VELCADE® (bortezomib) for Injection in its new indication and the
INTEGRILIN® (eptifibatide) Injection brand initiative launched at the Academy of Clinical Cardiology Annual Scientific Sessions.

Restructuring

We recorded restructuring charges of $1.1 million in the first quarter of 2005 compared to charges of $11.6 million in the same period in 2004. The
charges in both periods primarily relate to the recognition of the estimated remaining rental obligations, net of estimated sublease income, for facilities we no longer occupy.

We
anticipate total restructuring charges during 2005 of between approximately $5.0 million and $20.0 million relating to potential adjustments to our original estimates of
the remaining rental obligations for facilities we vacated based upon our ability to secure subtenants in the time and manner included in our original estimates.

26

---



Amortization of Intangibles

Amortization of intangible assets was $8.5 million in the first quarter of 2005 compared to $8.4 million in the same period in 2004. Amortization in
both periods relates to specifically identified intangible assets from the COR acquisition. We will continue to amortize the specifically identified intangible assets from our COR acquisition through
2015. We expect to incur amortization expense of approximately $35.0 million for each of the next five years.

Investment Income

Investment income decreased 30% to $4.4 million in the first quarter of 2005 from $6.4 million in the same period in 2004. The decrease is a result
of lower average balance of invested funds and less favorable market conditions resulting in lower yields.

Interest Expense

Interest expense decreased 4% to $2.6 million in the first quarter of 2005 from $2.7 million in the same period in 2004.

Gain on Sale of Equity Interest in Joint Venture

Through our acquisition of LeukoSite, we became a party to a joint venture partnership, Millennium and ILEX Partners, L.P., or M&I, for development of
Campath® (alemtuzumab) humanized monoclonal antibody. We sold our equity interest in M&I and in consideration for the sale,
we received an initial payment of $20.0 million in December 2001. During each of the second quarters of 2003 and 2002, we recorded additional gains of $40.0 million on our sale of
this equity interest based upon the achievement of predetermined sales targets of Campath. During the first quarter of 2004, we recorded the final $40.0 million gain related to our sale of this
equity interest based upon the achievement of predetermined 2004 sales targets of Campath. We will be entitled to additional payments from ILEX if sales of Campath in the United States after 2004
exceed specified annual thresholds. However, we currently do not expect that these thresholds will be achieved and therefore, we are unlikely to receive any future additional payments related to
Campath.

Liquidity and Capital Resources

We require cash to fund our operating expenses, to make capital expenditures, acquisitions and investments and to pay debt service, including principal and
interest and capital lease payments. We have also made strategic commitments to purchase debt and equity securities from some of our alliance collaborators in accordance with our Board of Directors'
approved policies and our business needs. These investment commitments are generally in smaller companies. We have and may in the future lose money in these investments and our ability to liquidate
these investments is in some cases very limited. We may also owe our partners milestone payments and royalties. We also have committed to fund development costs incurred by some of our collaborators.

We
have funded our cash requirements primarily through the following:



27

---





In
the future, we expect to continue to fund our cash requirements from some of these sources as well as from sales of other products, subject to receiving regulatory approval. We are
entitled to additional committed research and development funding under some of our strategic alliances. We believe the key factors that could affect our internal and external sources of cash are:



As
of March 31, 2005 we had $576.0 million in cash, cash equivalents and marketable securities. This excludes $9.1 million of interest-bearing marketable securities
classified as restricted cash on our balance sheet as of March 31, 2005, which primarily serve as collateral for letters of credit securing leased facilities.

|                                                 |  | March 31,
2005 |         | December 31,
2004
|------------------------------------------------ |  | -------------- | ------- | -----------------
|
|Cash, cash equivalents and marketable securities |  | $              | 576,021 |                  
|Working capital                                  |  |                | 632,853 |                  

|                                                              |                      | Three Months Ended |         
|------------------------------------------------------------- | -------------------- | ------------------ | --------
|
|Cash provided by (used in):                                   |                      |                    |         
|                                                              | Operating activities |                    | (110,207
|                                                              | Investing activities |                    | 111,330 
|                                                              | Financing activities |                    | (1,769  
|Capital expenditures (included in investing activities above) |                      | (4,312             | )       

Cash Flows

The principal use of cash in operating activities in both 2005 and 2004 was to fund our net loss. In January 2005, we paid SGP approximately
$49.3 million for advances SGP had made to COR for inventory purchases in prior years. Cash flows from operations can vary significantly due to various factors including changes in accounts
receivable, as well as changes in accounts payable and accrued expenses. The average collection period of our accounts receivable can vary and is dependent on various factors, including the type of
revenue and the payment terms related to those revenues.

Investing
activities provided cash of $111.3 million in 2005 and $21.0 million in 2004. The principal source of funds during both 2005 and 2004 was from the proceeds from
sales and maturities of marketable securities.

We
used $1.8 million of cash in financing activities in 2005 primarily to make principal payments on our capital leases. Financing activities provided cash of $9.7 million
in 2004. The principal source was from the sales of common stock to our employees.

28

---



We
believe that our existing cash and cash equivalents and the anticipated cash payments from our product sales, co-promotion revenue and current strategic alliances will be sufficient
to support our expected operations, fund our debt service and capital lease obligations and fund our capital commitments for at least the next several years.

Contractual Obligations

There have been no significant changes, other than noted above, to our contractual obligations and commercial commitments included in our Form 10-K as of
December 31, 2004.

As
of March 31, 2005, we did not have any financing arrangements that were not reflected in our balance sheet.

Subsequent Event

In April 2005, we recorded a realized gain of approximately $10.5 million upon the sale of our cost method investment in TransForm
Pharmaceuticals, Inc. ("TransForm"). We expect to record an additional realized gain of approximately $2.8 million in the second half of 2006 upon the final settlement of the escrowed
portion of the sale proceeds. TransForm, a company specializing in the discovery of formulations and novel crystalline forms of drug molecules, was acquired by Johnson & Johnson in a
cash-for-stock transaction that closed in April 2005.

29

---





RISK FACTORS THAT MAY AFFECT RESULTS

This Quarterly Report on Form 10-Q and certain other communications made by us contain forward-looking statements, including statements about our growth
and future operating results, discovery and development of products, strategic alliances and intellectual property. For this purpose, any statement that is not a statement of historical fact should be
considered a forward-looking statement. We often use the words "believe," "anticipate," "plan," "expect," "intend," "may," "will" and similar expressions to help identify forward-looking statements.

We
cannot assure investors that our assumptions and expectations will prove to have been correct. Important factors could cause our actual results to differ materially from those
indicated or implied by forward-looking statements. Such factors that could cause or contribute to such differences include those factors discussed below. We undertake no intention or obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Regulatory Risks

Our business may be harmed if we do not obtain approval to market VELCADE® (bortezomib) for Injection for additional therapeutic uses.

An important part of our strategy to grow our business is to market VELCADE for additional indications. To do so, we will need to successfully conduct clinical
trials and then apply for and obtain the appropriate regulatory approvals. If we are unsuccessful in our clinical trials, or we experience a delay in obtaining or are unable to obtain authorizations
for expanded uses of VELCADE, our revenues may not grow as expected and our business and operating results will be harmed.

We may not be able to obtain approval in additional countries to market VELCADE.

VELCADE is currently approved for marketing in the United States, the countries of the European Union and other countries. If we are not able to obtain approval
to market VELCADE in additional countries, we will lose the opportunity to sell in those countries and will not be able to earn potential milestone payments under our agreement with Ortho Biotech or
collect potential distribution fees on sales of VELCADE by Ortho Biotech in those countries.

We may not be able to obtain marketing approval for products resulting from our development efforts and we may face challenges to the exclusivity of our marketing approvals.

The products that we are developing require research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any
commercial sales. This process is expensive and lengthy, and can often take a number of years. In some cases, the length of time that it takes for us to achieve various regulatory approval milestones
affects the payments that we are eligible to receive under our strategic alliance agreements.

We
may need to successfully address a number of technological challenges in order to complete development of our products. Moreover, these products may not be effective in treating any
disease or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use.

In
some cases, we may experience challenges to the extension of exclusivity of our marketing approval. For example, with respect to INTEGRILIN, regulatory authorities in Luxembourg
instituted a claim to reduce the effective term of supplemental protection certificates for INTEGRILIN in the European Community from 2014 to 2012. That claim was denied by the court of first instance
in Europe. That denial was appealed to the European Court of Justice. In April 2005 the European Court of Justice decided against us and the term of the supplemental protection certificates
covering INTEGRILIN can now be shortened to 2012 in any particular European Community Member State in

30

---



which
a subsequent action requesting enforcement of the appellate decision was filed and decided against us. Shortening of such term could allow earlier generic competition in any such Member State.

If we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, our products could be subject to restrictions or
withdrawal from the market.

Any product for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data and promotional activities for such
product, is subject to continual review and periodic inspections by the FDA, and other regulatory bodies. Later discovery of previously unknown problems or safety issues with our products or
manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, the
imposition of civil or criminal penalties or a refusal by the FDA and other regulatory bodies to approve pending applications for marketing approval of new drugs or supplements to approved
applications. As with any recently approved therapeutic product, we expect that our knowledge of the safety profile for VELCADE will expand after wider usage and the possibility exists of patients
receiving VELCADE treatment experiencing unexpected serious adverse events, which could have a material adverse effect on our business.

We
are a party to collaborations that transfer responsibility for specified regulatory requirements, such as filing and maintenance of marketing authorizations and safety reporting to
our collaborators. If our collaborators do not fulfill these regulatory obligations, products, including VELCADE or INTEGRILIN, could be withdrawn from the market, which would have a material adverse
effect on our business.

Some of our products may be based on new technologies which may affect our ability or the time we require to obtain necessary regulatory approvals.

Products that result from our research and development programs may be based on new technologies and new therapeutic approaches that have not been extensively
tested in humans. The regulatory requirements governing these types of products may be more rigorous than for conventional products. As a result, we may experience a longer regulatory process in
connection with any products that we develop based on these new technologies or new therapeutic approaches.

Risks Relating to Our Business, Strategy and Industry

Our revenues over the next several years will be materially dependent on the commercial success of VELCADE® (bortezomib) for Injection and INTEGRILIN®
(eptifibatide) Injection.

Our revenues over the next several years will be materially dependent on the commercial success of our two currently marketed products: VELCADE and INTEGRILIN.
VELCADE was approved by the FDA in May 2003 and commercially launched in the United States shortly after that date. Marketing of VELCADE outside the United States commenced in
April 2004. INTEGRILIN has been on the market in the United States since June 1998. Marketing of INTEGRILIN outside the United States commenced in mid-1999.

Because
of the recent introduction of VELCADE, we have limited experience as to the sales levels of this product. Our business plan contemplates obtaining marketing authorization to sell
VELCADE in many countries for the treatment of all patients with multiple myeloma and both in the United States and abroad for other indications. We will be adversely affected if VELCADE does not
receive such approvals.

31

---



We
will not achieve our business plan, and we may be forced to scale back our operations and research and development programs, if:



We face substantial competition, and others may discover, develop or commercialize products before or more successfully than we do.

The fields of biotechnology and pharmaceuticals are highly competitive. Many of our competitors are substantially larger than we are, and these competitors have
substantially greater capital resources, research and development staffs and facilities than we have. Furthermore, many of our competitors are more experienced than we are in drug research, discovery,
development and commercialization, obtaining regulatory approvals and product manufacturing and marketing. As a result, our competitors may discover, develop and commercialize pharmaceutical products
before or in a shorter timeframe than we do. In addition, our competitors may discover, develop and commercialize products that make the products that we or our collaborators have developed or are
seeking to develop and commercialize non-competitive or obsolete.

With
respect to VELCADE, we face competition from Celgene Corporation's Thalomid® (thalidomide) and its derivatives, a treatment approved for complications associated with
leprosy which is increasingly used for multiple myeloma based on data published in peer-reviewed publications. Celgene has filed an sNDA for Thalomid for the treatment of multiple myeloma that was
accepted by the FDA for review. We also face competition for VELCADE from traditional chemotherapy treatments, and there are other potentially competitive therapies for VELCADE that are in late-stage
clinical development for the treatment of multiple myeloma including Celgene's Revlimid®. In addition, multiple myeloma therapies in development may reduce the number of patients available
for VELCADE treatment through enrollment of these patients in clinical trials of these potentially competing products.

Due
to the incidence and severity of cardiovascular diseases, the market for therapeutic products that address these diseases is large, and we expect the already intense competition in
this field to increase. Our most significant competitors are major pharmaceutical companies and biotechnology companies. The two products that compete directly with INTEGRILIN in the GP IIb-IIIa
inhibitor market segment are ReoPro® (abciximab), which is produced by Johnson & Johnson and sold by Johnson & Johnson and Eli Lilly and Company, and Aggrastat®
(tirofiban HCl), which is produced and sold by Merck & Co., Inc. outside of the United States and by Guilford Pharmaceuticals, Inc. in the United States.

Other
competitive factors that could negatively affect INTEGRILIN include:



32

---





Sales of INTEGRILIN® (eptifibatide) Injection and possibly VELCADE® (bortezomib) for Injection in particular reporting periods may be affected by
fluctuations in inventory, allowances and buying patterns.

A significant portion of INTEGRILIN domestic pharmaceutical sales is made by SGP to major drug wholesalers. These sales are affected by fluctuations in the buying
patterns of these wholesalers and the corresponding changes in inventory levels maintained by them. Inventory levels held by these wholesalers may fluctuate significantly from quarter to quarter. If
these wholesalers build inventory levels excessively in any quarter, sales to the wholesalers in future quarters may unexpectedly decrease notwithstanding steady prescriber demand. Because SGP
currently manages product distribution, we have limited insight into or control over forces affecting changes in distributor inventory levels. If SGP does not appropriately manage this distribution,
we and SGP may not realize our sales goals for the product and increased returns could reduce the co-promotion revenue we recognize and adversely affect our business.

We
recently began distributing VELCADE in the U.S. through a sole-source distribution model, where we sell directly to a third party who in turn distributes to the wholesaler base. Our
product inventory levels may fluctuate in the short-term as our current wholesalers familiarize themselves with these new distribution logistics.

Additionally,
we and our commercial collaborators make provisions at the time of sale of both VELCADE® (bortezomib) for Injection and INTEGRILIN® (eptifibatide)
Injection for all discounts, rebates and estimated sales allowances based on historical experience
updated for changes in facts and circumstances, as appropriate. To the extent these allowances are incorrect, we may need to adjust our estimates, which could have a material impact on the timing and
actual revenue we are able to recognize from these sales.

Because
fewer medical procedures are typically performed in the summer months, demand for INTEGRILIN could generally be lower during these months. These fluctuations in sales of
INTEGRILIN could have a material adverse effect on our results of operations for particular reporting periods. It is possible that sales of VELCADE could be similarly affected by fluctuations in
buying patterns.

Because our research and development projects are based on new technologies and new therapeutic approaches that have not been extensively tested in humans, it is possible that
our discovery process will not result in commercial products.

The process of discovering drugs based upon genomics and other new technologies is new and evolving rapidly. We focus a portion of our research on diseases that
may be linked to several or many genes working in combination or to unprecedented targets. Both we and the general scientific and medical communities have only a limited understanding of the role that
genes play in these diseases. To date, we have not commercialized any products discovered through our genomics research, and we may not be successful in doing so in the future. In addition, relatively
few products based on gene discoveries have been developed and commercialized by others. Rapid technological development by us or others may result in compounds, products or processes becoming
obsolete before we recover our development expenses. Further, manufacturing costs or products based on these new technologies may make products uneconomical to commercialize.

33

---



If our clinical trials are unsuccessful, or if they experience significant delays, our ability to commercialize products will be impaired.

We must provide the FDA and foreign regulatory authorities with preclinical and clinical data demonstrating that our products are safe and effective before they
can be approved for commercial sale. Clinical development, including preclinical testing, is a long, expensive and uncertain process. It may take us several years to complete our testing, and failure
can occur at any stage of testing. Interim results of preclinical or clinical studies do not necessarily predict their final results, and acceptable results in early studies might not be seen in later
studies. Any preclinical or clinical test may fail to produce results satisfactory to the FDA. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent
regulatory approval. Negative or inconclusive results from a preclinical study or clinical trial, adverse medical events during a clinical trial or safety issues resulting
from products of the same class of drug could cause a preclinical study or clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the program are
successful. For example, in December 2003 we decided to stop further accrual to a phase II trial examining VELCADE® (bortezomib) for Injection in colorectal cancer because interim
findings produced results that did not meet the pre-specified efficacy criteria for continuation of study accrual.

We
may not complete our planned preclinical or clinical trials on schedule or at all. We may not be able to confirm the safety and efficacy of our potential drugs in long-term clinical
trials, which may result in a delay or failure to commercialize our products. In addition, due to the substantial demand for clinical trial sites in the cardiovascular area, we may have difficulty
obtaining a sufficient number of appropriate patients or clinician support to conduct our clinical trials as planned. A number of additional events could delay the completion of our clinical trials,
including conditions imposed on us by the FDA or foreign regulatory authorities regarding the scope or design of our clinical trials, lower than anticipated retention rates for patients in our
clinical trials, insufficient supply or deficient quality of our product candidates or other materials necessary to conduct our clinical trials or the failure of our third-party contractors to comply
with regulatory requirements or otherwise meet their contractual obligations to us in a timely manner. As a result, we may have to expend substantial additional funds to obtain access to resources or
delay or modify our plans significantly. Our product development costs will increase if we experience delays in testing or approvals. Significant clinical trial delays could allow our competitors to
bring products to market before we do and impair our ability to commercialize our products or potential products.

If third parties on which we rely for clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or
commercialize our product candidates.

We depend on independent clinical investigators and, in some cases, contract research organizations and other third-party service providers to conduct the
clinical trials of our product candidates and expect to continue to do so. We rely heavily on these parties for successful execution of our clinical trials, but we do not control many aspects of their
activities. Nonetheless, we are responsible for confirming that each of our clinical trials is conducted in accordance with the general investigational plan and protocol. Our reliance on these third
parties that we do not control does not relieve us of our responsibility to comply with the regulations and standards of the FDA relating to good clinical practices. Third parties may not complete
activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or the applicable trials plans and protocols. The failure of these third parties to carry out
their obligations could delay or prevent the development, approval and commercialization of our product candidates or result in enforcement action against us.

34

---



Because many of the products that we are developing are based on new technologies and therapeutic approaches, the market may not be receptive to these products upon their
introduction.

The commercial success of any of our products for which we may obtain marketing approval from the FDA or other regulatory authorities will depend upon their
acceptance by the medical community and third party payors as clinically useful, cost-effective and safe. Many of the products that we are developing are based upon new technologies or therapeutic
approaches. As a result, it may be more difficult for us to achieve market acceptance of our products, particularly the first products that we introduce to the market based on new technologies and
therapeutic approaches. Our efforts to educate the medical community on these potentially unique approaches may require greater resources than would be typically required for products based on
conventional technologies or therapeutic approaches. The safety, efficacy, convenience and cost-effectiveness of our products as compared to competitive products will also affect market acceptance.

Because of the high demand for talented personnel within our industry, we could experience delays and/or incur substantial costs to recruit employees necessary for our success
and growth.

Because competition for talented employees within our industry is fierce, we may not be successful in hiring, retaining or promptly replacing key management,
sales, marketing and technical personnel. Any failure to expediently fill our needs for key personnel could have a material adverse effect on our business.

Risks Relating to Our Financial Results and Need for Financing

We have incurred substantial losses and expect to continue to incur losses. We will not be successful unless we reverse this trend.

We have incurred net losses $36.4 million and $40.6 million for the three months ended March 31, 2005 and 2004, respectively, net losses of
$252.3 million for the year ended December 31, 2004, net losses of $483.7 million for the year ended December 31, 2003 and net losses of $590.2 million for the year
ended December 31, 2002. We expect to continue to incur substantial operating losses in future periods. Prior to our acquisition of COR, substantially all of our revenues resulted from payments
from collaborators, and not from the sale of products.

We
expect to continue to incur significant expenses in connection with our research and development programs and commercialization activities. As a result, we will need to generate
significant revenues to help fund these costs and achieve profitability. Our ability to achieve profitability would be adversely impacted if our acquired intangible assets and goodwill, primarily
resulting from our acquisition of COR, became impaired as a result of reduced market capitalization or product failures or withdrawals. We cannot be certain whether or when we will become profitable
because of the significant uncertainties with respect to our ability to generate revenues from the sale of products and from existing and potential future strategic alliances.

We may need additional financing, which may be difficult to obtain. Our failure to obtain necessary financing or doing so on unattractive terms could adversely affect our
business and operations.

We will require substantial funds to conduct research and development, including preclinical testing and clinical trials of our potential products. We will also
require substantial funds to meet our obligations to our collaborators, manufacture and market products that are approved for commercial sale, including INTEGRILIN® (eptifibatide)
Injection and VELCADE® (bortezomib) for Injection, and meet our debt service obligations. Additional financing may not be available when we need it or may not be available on favorable
terms.

35

---



If
we are unable to obtain adequate funding on a timely basis, we may have to delay or curtail our research and development programs or our product commercialization activities. We could
be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to specified technologies, product candidates or products which we would otherwise
pursue on our own.

Our indebtedness and debt service obligations may adversely affect our cash flow and otherwise negatively affect our operations.

At March 31, 2005, we had approximately $105.5 million of outstanding convertible debt and $87.8 million of capital lease obligations. During
each of the last five years, our earnings were insufficient to cover our fixed charges. We will be required to make interest payments on our outstanding convertible notes totaling approximately
$11.2 million over the next three years.

We
may in the future incur additional indebtedness, including long-term debt, credit lines and property and equipment financings to finance capital expenditures. We intend to satisfy our
current and future
debt service obligations from cash generated by our operations, our existing cash and investments and, in the case of principal payments at maturity, funds from external sources. We may not have
sufficient funds and we may be unable to arrange for additional financing to satisfy our principal or interest payment obligations when those obligations become due. Funds from external sources may
not be available on acceptable terms, or at all.

Our
indebtedness could have significant additional negative consequences, including:



If we do not achieve the anticipated benefits of our restructuring, or if the costs of this restructuring exceed anticipated levels, our business could be harmed.

In December 2002 and June 2003, we announced a restructuring designed to focus our resources on development and commercialization of product
opportunities and achieving our goal of becoming profitable in the future. We may not achieve the cost savings anticipated from the restructuring because such savings are difficult to predict and
speculative in nature. In 2003, we recorded approximately $191.0 million related to this restructuring and in 2004, we recorded approximately $38.0 million related to this restructuring.
We expect to record additional restructuring charges during 2005 of between $5.0 million and $20.0 million. While we believe this estimate to be reasonable, it is possible that the
actual charges will exceed this range. For example, we may not be able to lease facilities that we have closed or plan to close in connection with the restructuring as quickly or on as favorable terms
as we anticipated.

36

---



Risks Relating to Collaborators

We depend significantly on our collaborators to work with us to develop and commercialize products.

We market and sell INTEGRILIN® (eptifibatide) Injection through alliances with SGP and GSK. Outside of the United States, we commercialize
VELCADE® (bortezomib) for Injection through an alliance with Ortho Biotech. We conduct substantial discovery and development activities through strategic alliances, including with Ortho
Biotech for the ongoing development of VELCADE, and with SGP for the ongoing development of INTEGRILIN. We expect to enter into additional alliances in the future, especially in connection with
product commercialization. The success of our alliances depends heavily on the efforts and activities of our collaborators.

Each
of our collaborators has significant discretion in determining the efforts and resources that it will apply to the alliance and the degree to which it shares financial and product
sales and inventory information. Our existing and any future alliances may not be scientifically or commercially successful.

The
risks that we face in connection with these existing and any future alliances include the following:



We may not be successful in establishing additional strategic alliances, which could adversely affect our ability to develop and commercialize products.

An important element of our business strategy is entering into strategic alliances for the development and commercialization of selected products. In some
instances, if we are unsuccessful in reaching an agreement with a suitable collaborator, we may fail to meet all of our business objectives for the applicable product or program. We face significant
competition in seeking appropriate collaborators. Moreover, these alliance arrangements are complex to negotiate and time-consuming to document. We may not be successful in our efforts to establish
additional strategic alliances or other alternative arrangements. The terms of any additional strategic alliances or other arrangements that we establish may not be favorable to us. Moreover, such
strategic alliances or other arrangements may not be successful.

37

---



Risks Relating to Intellectual Property

If we are unable to obtain patent protection for our discoveries, the value of our technology and products will be adversely affected. If we infringe patent or other
intellectual property rights of third parties, we may not be able to develop and commercialize our products or the cost of doing so may increase.

Our patent positions, and those of other pharmaceutical and biotechnology companies, are generally uncertain and involve complex legal, scientific and factual
questions.

Our
ability to develop and commercialize products depends in significant part on our ability to:



There is significant uncertainty about the validity and permissible scope of patents in our industry, which may make it difficult for us to obtain patent protection for our
discoveries.

The validity and permissible scope of patent claims in the pharmaceutical and biotechnology fields, including the genomics field, involve important unresolved
legal principles and are the subject of public policy debate in the United States and abroad. For example, there is significant uncertainty both in the United States and abroad regarding the
patentability of gene sequences in the absence of functional data and the scope of patent protection available for full-length genes and partial gene sequences. Moreover, some groups have made
particular gene sequences available in publicly accessible databases. These and other disclosures may adversely affect our ability to obtain patent protection for gene sequences claimed by us in
patent applications that we file subsequent to such disclosures. There is also some uncertainty as to whether human clinical data will be required for issuance of patents for human therapeutics. If
such data are required, our ability to obtain patent protection could be delayed or otherwise adversely affected.

Third parties may own or control patents or patent applications and require us to seek licenses, which could increase our development and commercialization costs, or prevent us
from developing or marketing our products.

We may not have rights under some patents or patent applications related to some of our existing and proposed products or processes. Third parties may own or
control these patents and patent applications in the United States and abroad. Therefore, in some cases, such as those described below, in order to develop, manufacture, sell or import some of our
existing and proposed products or processes, we or our collaborators may choose to seek, or be required to seek, licenses under third-party patents issued in the United States and abroad, or those
that might issue from United States and foreign patent applications. In such event, we would be required to pay license fees or royalties or both to the
licensor. If licenses are not available to us on acceptable terms, we or our collaborators may not be able to develop, manufacture, sell or import these products or processes.

Our
MLN02 and MLN1202 product candidates are humanized monoclonal antibodies. Our product candidate MLN2704 also includes a recombinant antibody. We are aware of third-party patents and
patent applications that relate to humanized or modified antibodies, products useful for making humanized or modified antibodies and processes for making and using recombinant antibodies. With

38

---



respect
to MLN2704, we are also aware of third-party patent applications relating to anti-PSMA antibodies.

With
respect to VELCADE® (bortezomib) for Injection and other proteasome inhibitors in the treatment of myocardial infarctions, we are aware of the existence of a potentially
interfering patent application filed by a third party. In addition, on June 26, 2002, Ariad Pharmaceuticals, Inc. sent to us and approximately 50 other parties a letter offering a
sublicense for the use of United States Patent No. 6,410,516, which is exclusively licensed to Ariad. If this patent is valid and Ariad successfully sues us for infringement, we would require a
license from Ariad in order to manufacture and market VELCADE.

We may become involved in expensive patent litigation or other proceedings, which could result in our incurring substantial costs and expenses or substantial liability for
damages or require us to stop our development and commercialization efforts.

There has been substantial litigation and other proceedings regarding the patent and other intellectual property rights in the pharmaceutical and biotechnology
industries. We may become a party to patent litigation or other proceedings regarding intellectual property rights. For example, we believe that we hold patent applications that cover genes that are
also claimed in patent applications filed by others. Interference proceedings before the United States Patent and Trademark Office may be necessary to establish which party was the first to invent
these genes.

The
cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such
litigation or proceedings more effectively than we can because of their substantially greater financial resources. If a patent litigation or other proceeding is resolved against us, we or our
collaborators may be enjoined from developing, manufacturing, selling or importing our products or processes without a license from the other party and we may be held liable for significant damages.
We may not be able to obtain any required license on commercially acceptable terms or at all.

Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
Patent litigation and other proceedings may also absorb significant management time.

Our patent protection for any compounds that we seek to develop may be limited to a particular method of use or indication such that, if a third party were to obtain approval
of the compound for use in another indication, we could be subject to competition arising from off-label use.

Although we generally seek the broadest patent protection available for our proprietary compounds, we may not be able to obtain patent protection for the actual
composition of any particular compound and may be limited to protecting a new method of use for the compound or otherwise restricted in our ability to prevent others from exploiting the compound. If
we are unable to obtain patent protection for the actual composition of any compound that we seek to develop and commercialize and must rely on method of use patent coverage, we would likely be unable
to prevent others from manufacturing or marketing that compound for any use that is not protected by our patent rights. If a third party were to receive marketing approval for the compound for another
use, physicians could nevertheless prescribe it for indications that are not described in the product's labeling or approved by the FDA or other regulatory authorities. Even if we have patent
protection of the prescribed indication, as a practical matter, we would have little recourse as a result of this off-label use. In that event, our revenues from the commercialization of the compound
would likely be adversely affected.

39

---



If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.

We are a party to various license agreements. In particular, we license rights to patents for the formulation of VELCADE® (bortezomib) for Injection,
issued U.S. patents covering MLN2704 and issued patents relating to MLN518. We may enter into additional licenses in the future. Our existing licenses impose, and we expect future licenses will
impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in
which event we might not be able to market any product that is covered by the licensed patents.

40

---





Risks Relating to Product Manufacturing, Marketing and Sales

Because we have limited sales, marketing and distribution experience and capabilities, we are dependent on third parties to successfully perform these functions on our behalf,
or we may be required to incur significant costs and devote significant efforts to augment our existing capabilities.

We are marketing and selling VELCADE in the United States solely through our cancer-specific sales force and without a collaborator. Our success in selling
VELCADE will depend heavily on the performance of this sales force. In areas outside the United States where VELCADE has received approval, Ortho Biotech or its affiliates market VELCADE. As a result,
our ability to earn revenue related to VELCADE outside of the United States will depend heavily on Ortho Biotech.

We
have a specialty cardiovascular sales force that markets INTEGRILIN® (eptifibatide) Injection with SGP in the United States. GSK exclusively markets INTEGRILIN in Europe
and SGP markets INTEGRILIN in areas outside of the United States and Europe. Our success in receiving co-promotion revenue royalties and milestone payments from sales of INTEGRILIN will depend heavily
on the marketing efforts of these sales forces.

During
September 2004, we initiated the process, contemplated by the original agreement with SGP, to transition United States distribution responsibilities for INTEGRILIN from SGP
to us. If we are not able to successfully distribute the product after this transition, INTEGRILIN sales could decline and our business could be substantially harmed.

Depending
on the nature of the products for which we obtain marketing approval, we may need to rely significantly on sales, marketing and distribution arrangements with our collaborators
and other third parties. For example, some types of pharmaceutical products require a large sales force and extensive marketing capabilities for effective commercialization. If in the future we elect
to perform sales, marketing and distribution functions for these types of products ourselves, we would face a number of additional risks, including the need to recruit a large number of additional
experienced marketing and sales personnel.

Because we have no commercial manufacturing capabilities, we will continue to be dependent on third-party manufacturers to manufacture products for us, or we will be required
to incur significant costs and devote significant efforts to establish our own manufacturing facilities and capabilities.

We have no commercial-scale manufacturing capabilities. In order to continue to develop products, apply for regulatory approvals and commercialize products, we
will need to develop, contract for or otherwise arrange for the necessary manufacturing capabilities.

We
currently rely upon third parties to produce material for preclinical testing purposes and expect to continue to do so in the future. We also currently rely and expect to continue to
rely, upon other third parties, potentially including our collaborators, to produce materials required for clinical trials and for the commercial production of our products.

There
are a limited number of contract manufacturers that operate under the FDA's good manufacturing practices regulations capable of manufacturing our products. If we are unable to
arrange for third-party manufacturing of our products, or to do so on commercially reasonable terms, we may not be able to complete development of our products or commercialize them.

Reliance
on third-party manufacturers entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the third party for regulatory
compliance, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control and the possibility of termination or non-renewal of the agreement by the
third party, based on its own business priorities, at a time that is costly or inconvenient for us.

41

---



We
may in the future elect to manufacture some of our products in our own manufacturing facilities. We would need to invest substantial additional funds and recruit qualified personnel
in order to build or lease and operate any manufacturing facilities.

Because we have no commercial manufacturing capability for VELCADE® (bortezomib) for Injection, we are dependent on third parties to produce product sufficient to
meet market demand.

We rely on third-party contract manufacturers to manufacture, fill/finish and package VELCADE for both commercial purposes and for all clinical trials. We have
established long-term supply relationships for the production of commercial supplies of VELCADE. We work with one manufacturer, with whom we have a long-term supply agreement, to complete fill/finish
for VELCADE. If any of our current third party manufacturers performing production and fill/finish for VELCADE are unable or unwilling to continue performing these services for us and we are unable to
find a replacement manufacturer or in the future we are otherwise unable to contract with manufacturers to produce commercial supplies of VELCADE in a cost-effective manner, we could run out of
VELCADE for commercial sale and clinical trials and our business could be substantially harmed.

We face challenges in connection with the manufacture of INTEGRILIN® (eptifibatide) Injection; if we do not meet these challenges, our revenues and income will be
adversely affected.

We have no manufacturing facilities for INTEGRILIN and, accordingly, rely on third-party contract manufacturers for the clinical and commercial production of
INTEGRILIN. We have two manufacturers that currently provide us with eptifibatide, the active ingredient necessary to make INTEGRILIN. Solvay, one of the current manufacturers, owns the process
technology used by it and the other manufacturer for the production of bulk product. As a result, until we have an approved alternative process technology, we will be reliant on these manufacturers.
We have one manufacturer that currently performs fill/finish services for INTEGRILIN. We are qualifying a second fill/finish supplier and we have identified an alternative packaging supplier to serve
as future sources of supply for the United States. The inability of our current manufacturer to continue its fill/finish services or our inability to secure alternative manufacturers could adversely
affect the supply of INTEGRILIN and, thereby, harm our business.

We
expect to seek approval of an alternate process technology and to enhance the availability of manufacturing capabilities for INTEGRILIN. We cannot quantify the time or expense that
may ultimately be required to obtain approval for an alternate process technology, but it is possible that such time or expense could be substantial. Moreover, we may not be able to implement any new
process technology successfully.

In
order to mitigate the risk of supply interruption, our manufacturing plans and commercialization strategy for INTEGRILIN include the addition of extra capacity for the manufacture of
INTEGRILIN as described above. We are currently engaged in finalizing third-party manufacturing arrangements on commercially reasonable terms. We may not be able to do so, and, even if such
arrangements are established, if demand for INTEGRILIN does not meet our forecasts, the manufacturing cost could become more expensive on a per unit basis.

If we fail to obtain an adequate level of reimbursement for our products by third-party payors, there may be no commercially viable markets for our products.

The availability and levels of reimbursement by governmental and other third-party payors affect the market for any pharmaceutical product or health care service.
These third-party payors continually attempt to contain or reduce the costs of health care by challenging the prices charged for medical products and services. In some foreign countries, particularly
the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. We may not be able to sell

42

---



our
products as profitably as we expect if we are required to sell our products at lower than anticipated prices or reimbursement is unavailable or limited in scope or amount.

In
particular, third-party payors could lower the amount that they will reimburse hospitals or doctors to treat the conditions for which the FDA has approved INTEGRILIN or VELCADE. If
they do, pricing levels or sales volumes of INTEGRILIN or VELCADE may decrease. In addition, if we fail to comply with the rules applicable to the Medicaid and Medicare programs, we could be subject
to the imposition of civil or criminal penalties or exclusion from these programs.

In
foreign markets, a number of different governmental and private entities determine the level at which hospitals will be reimbursed for administering INTEGRILIN®
(eptifibatide) Injection and VELCADE® (bortezomib) for Injection to insured patients. If these levels are set, or reset, too low, it may not be possible to sell INTEGRILIN or VELCADE at a
profit in these markets.

In
both the United States and other foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system. For example, the Medicare
Prescription Drug and Modernization Act of 2003 and its implementing regulations impose new requirements for the distribution and pricing of prescription drugs which may affect the marketing of our
products. These new requirements have created uncertainty among oncologists and could impact sales levels of VELCADE as oncologists adapt to the new reimbursement model. Further proposals are also
likely. The current uncertainty and the potential for adoption of additional proposals could affect the timing of product revenue, our ability to raise capital, obtain additional collaborators and
market our products.

In
addition, we believe that the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of our present and future products,
which may adversely affect product sales. Further, when a new therapeutic product is approved, the availability of governmental or private reimbursement for that product is uncertain, as is the amount
for which that
product will be reimbursed. We cannot predict the availability or amount of reimbursement for our product candidates, and current reimbursement policies for INTEGRILIN or VELCADE could change at any
time.

We face a risk of product liability claims and may not be able to obtain insurance.

Our business exposes us to the risk of product liability claims that is inherent in the manufacturing, testing and marketing of human therapeutic products. In
particular, INTEGRILIN and VELCADE are administered to patients with serious diseases who have a high incidence of mortality. Although we have product liability insurance that we believe is
appropriate, this insurance is subject to deductibles, co-insurance requirements and coverage limitations and the market for such insurance is becoming more restrictive. We may not be able to obtain
or maintain adequate protection against potential liabilities. If we are unable to obtain insurance at acceptable cost or otherwise protect against potential product liability claims, we will be
exposed to significant liabilities, which may materially and adversely affect our business and financial position. These liabilities could prevent or interfere with our product commercialization
efforts.

Guidelines and recommendations can affect the use of our products.

Government agencies promulgate regulations and guidelines directly applicable to us and to our products. In addition, professional societies, practice management
groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the health care and patient
communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies.
Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients and health care providers could result in
decreased use of our products.

43

---



Risks Relating to an Investment in Our Common Stock

The trading price of our securities could be subject to significant fluctuations.

The trading price of our common stock has been quite volatile, and may be volatile in the future. During 2004, our common stock traded as high as $19.87 per share
and as low as $9.88 per share. Factors such as announcements of our or our competitors' operating results, data from our competitors' clinical trial results, changes in our prospects, market
conditions for biopharmaceutical stocks in general and analyst recommendations could have a significant impact on the future trading prices of our common stock.

In
particular, the trading price of the common stock of many biopharmaceutical companies, including ours, has experienced extreme price and volume fluctuations, which have at times been
unrelated to the operating performance of such companies whose stocks were affected. Some of the factors that may cause volatility in the price of our securities include:



The
price of our securities may also be affected by the estimates and projections of the investment community and our ability to meet or exceed the financial projections we provide to
the public. The price may also be affected by general economic and market conditions, and the cost of operations in our product markets. While we cannot predict the individual effect that these
factors may have on the price of our securities, these factors, either individually or in the aggregate, could result in significant variations in price during any given period of time. We can not
assure you that these factors will not have an adverse effect on the trading price of our common stock.

We have anti-takeover defenses that could delay or prevent an acquisition and could adversely affect the price of our common stock.

Provisions of our certificate of incorporation and bylaws and of Delaware law could have the effect of delaying, deferring or preventing an acquisition of our
company. For example, we have divided our board of directors into three classes that serve staggered three-year terms, we may issue shares of our authorized "blank check" preferred stock and our
stockholders are limited in their ability to call special stockholder meetings. In addition, we have issued preferred stock purchase rights that would adversely affect the economic and voting
interests of a person or group that seeks to acquire us or a 15% or greater interest in our common stock without negotiations with our board of directors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We manage our fixed income investment portfolio in accordance with our Policy for Securities Investments, or Investment Policy, that has been approved by our
Board of Directors. The primary

44

---



objectives
of our Investment Policy are to preserve principal, maintain a high degree of liquidity to meet operating needs, and obtain competitive returns subject to prevailing market conditions.
Investments are made primarily in investment-grade corporate bonds with effective maturities of three years or less, asset-backed debt securities and U.S. government agency debt securities. These
investments are subject to risk of default, changes in credit rating and changes in market value. These investments are also subject to interest rate risk and will decrease in value if market interest
rates increase. A hypothetical 100 basis point increase in interest rates would result in an approximate $9.1 million decrease in the fair value of our investments as of March 31, 2005.
However, due to the conservative nature of our investments and relatively short effective maturities of debt instruments, interest rate risk is mitigated. Our Investment Policy specifies credit
quality standards for our investments and limits the amount of exposure from any single issue, issuer or type of investment. We do not own derivative financial instruments in our investment portfolio.

As
of March 31, 2005, the fair value of our 4.5% notes, 5.0% notes and 5.5% notes approximates their carrying value. The interest rates on our convertible notes and capital lease
obligations are fixed and therefore not subject to interest rate risk.

We
have no derivative instruments outstanding as of March 31, 2005.

As
of March 31, 2005 we did not have any financing arrangements that were not reflected in our balance sheet.

Item 4. Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2005. In designing and evaluating our disclosure controls and procedures, management
recognized that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applied its judgment in evaluating the cost-benefit relationship of possible
controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that as of March 31, 2005, our disclosure controls and procedures were
(1) designed to ensure that material information relating to us is made known to our chief executive officer and chief financial officer by others, particularly during the period in which this
report was prepared and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

No
change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended
March 31, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

45

---





PART II OTHER INFORMATION

Item 6. Exhibits



The
exhibits listed in the Exhibit Index are included in this report.

46

---





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|                   | MILLENNIUM PHARMACEUTICALS, INC.(Registrant)                                                                                              
|------------------ | ------------------------------------------------------------------------------------------------------------------------------------------
|Dated: May 5, 2005 | /s/MARSHA H. FANUCCIMarsha H. Fanucci Senior Vice President and Chief Financial Officer
(principal financial and chief accounting officer)

47

---





Exhibit Index

|Exhibit No. |  | Description                                                                                                                         
|----------- |  | ------------------------------------------------------------------------------------------------------------------------------------
|31.1        |  | Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended
|31.2        |  | Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended
|32.1        |  | Statement Pursuant to 18 U.S.C. §1350                                                                                               
|32.2        |  | Statement Pursuant to 18 U.S.C. §1350                                                                                               

48

---